Amylyx Pharmaceuticals (AMLX) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Disc Medicine (IRON) over the past year, gaining 77.4% versus a loss of 18.9%. Disc Medicine is the larger company by market cap ($3.42 billion vs $3.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | IRON |
|---|---|---|
| Share price | $26.02 | $75.14 |
| Market cap | $3.35B | $3.42B |
| 1-day change | -0.69% | -1.27% |
| YTD return | +115.40% | -5.38% |
| 1-year return | +77.37% | -18.86% |
| 5-year return | — | -14.22% |
| EPS (TTM) | $-1.43 | $-6.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-144.74M | $-212.18M |
| 52-week high | $41.14 | $99.50 |
| 52-week low | $10.83 | $40.00 |
| Distance from 52-week high | -36.75% | -24.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.26% | +69.94% |
| Average volume | 1.53M | 951.56K |
| Shares outstanding | 128.56M | 45.54M |
| Employees | 136 | 173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed IRON by 96.2 percentage points over the past year.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees
AMLX vs IRON FAQ
Which is bigger, Amylyx Pharmaceuticals or Disc Medicine?
Disc Medicine (IRON) is larger, with a market capitalization of $3.42B compared with $3.35B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or IRON?
AMLX returned +77.37% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Disc Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.